Pharma Bets on Lp(a) Cholesterol for Next Heart Drug Blockbusters
Pharmaceutical giants Novartis, Amgen, and Eli Lilly are intensely developing drugs targeting Lp(a), a genetically determined form of cholesterol linked to a higher risk of heart attack than standard LDL. These drugs are in late-stage trials, with potential market revenues estimated up to $5.6 billion by 2032. However, the success hinges on clinical outcomes, as the trials are designed to prove prevention of major cardiovascular events. Currently, routine screening for Lp(a) is rare, despite growing advocacy from health organizations. Experts note that variations in trial designs may lead to varied results, and market adoption will depend on regulatory acceptance and physician guidelines.
Ad slot
Major pharmaceutical companies are heavily investing in drugs targeting Lp(a), a specific type of cholesterol considered more dangerous than standard LDL, due to its strong link with cardiovascular events.
The Danger of Lp(a) Cholesterol
Lp(a), or lipoprotein(a), was first identified in 1963. It poses a dual risk because it can both clog arteries and promote blood clots with a single particle. Research indicates that individuals with elevated Lp(a) have a more than twofold increased risk of heart attack compared to those with normal levels.
Genetic Basis: Lp(a) levels are primarily determined by genetics, meaning lifestyle changes like diet and exercise are less effective for reduction compared to managing LDL cholesterol.
Current Management: Doctors currently advise focusing on modifiable risk factors, such as lowering LDL cholesterol, managing blood pressure, and controlling obesity and diabetes.
Pharmaceutical Race to Target Lp(a)
Giants like Novartis, Amgen, and Eli Lilly are developing late-stage drugs designed to significantly lower Lp(a) levels, aiming to create a new class of blockbuster cardiology treatments. All three companies are conducting pivotal trials to determine if these drugs can prevent heart attacks and strokes.
Ad slot
Potential Market Size: If successful, these therapies could generate annual sales reaching an estimated $5.6 billion by 2032, according to industry estimates.
Efficacy Shown: These experimental drugs have already demonstrated the ability to slash Lp(a) levels by over 80% in preliminary stages.
Key Trials and Timelines
Each company's trial is designed differently, which experts note could lead to variations in the final clinical results. The outcomes of these trials are crucial for understanding the drug's true benefit.
Novartis: The company is awaiting results from its Phase 3 Horizon trial for pelacarsen. The readout was delayed because participants were not experiencing cardiovascular events as quickly as initially anticipated. The trial assesses if the drug prevents heart attacks and strokes in those with elevated Lp(a) and existing cardiovascular disease.
Amgen: Amgen's pivotal trial results for olpasiran were initially expected sooner but have seen timeline adjustments. The company has indicated a potential update on timing in early 2027.
Eli Lilly: Lilly anticipates sharing data from its Phase 3 trial for lepodisiran in 2029. Lilly is also pursuing other avenues, including a daily pill and gene-editing treatments.
Clinical Hurdles and Market Adoption
Despite the pharmaceutical focus, routine screening for Lp(a) remains uncommon. In 2024, fewer than 1% of U.S. adults were tested for it, and testing was geographically limited.
Advocacy: Leading cardiology organizations are beginning to recommend that every adult be tested for Lp(a) at least once in their lifetime.
Industry Caution: Some clinicians remain hesitant to screen patients for a condition for which no immediate treatment is available. The Family Heart Foundation is advocating for Lp(a) to be added to standard lipid panels.
Analyst View: While the scientific potential is high, analysts caution that building the market uptake will take time, especially since initial treatments may be restricted to high-risk patients with a history of cardiovascular events.
